ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, J Am Coll Cardiol, vol.70, issue.6, pp.776-803, 2017. ,
Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, vol.370, issue.15, pp.1383-92, 2014. ,
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial, Circulation, vol.131, issue.1, pp.34-42, 2015. ,
Spironolactone Metabolites in TOPCAT -New Insights into Regional Variation, N Engl J Med, vol.376, issue.17, pp.1690-1692, 2017. ,
Geographic differences in heart failure trials, Eur J Heart Fail, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01745546
Heart failure around the world, Eur J Heart Fail, 2019. ,
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, vol.341, issue.10, pp.709-726, 1999. ,
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur J Heart Fail, 2016. ,
Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, vol.364, issue.1, pp.11-21, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01742988
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial, Eur J Heart Fail, vol.21, issue.3, pp.345-351, 2019. ,
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial, J Card Fail, vol.24, issue.5, pp.313-320, 2018. ,
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial, JACC Heart Fail, vol.6, issue.8, pp.653-661, 2018. ,
Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study, Lancet, vol.2019, pp.1254-1263, 10205. ,
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), Circ Heart Fail, vol.7, issue.1, pp.51-59, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01739545
Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring! JACC Heart Fail, vol.7, pp.33-35, 2019. ,
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure), J Am Coll Cardiol, vol.62, issue.17, pp.1585-93, 2013. ,
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials, Eur J Heart Fail, vol.17, issue.4, pp.424-457, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01752255
Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative, Clin Res Cardiol, vol.108, issue.11, pp.1215-1225, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02510907
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction, JACC Heart Fail, vol.7, issue.1, pp.65-76, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02510424
Effect of eplerenone in patients with heart failure and reduced ejection fraction: Potential effect modification by abdominal obesity. Insight from EMPHASIS-HF trial, European Journal of Heart Failure, 2017. ,
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure, ATLAS Study Group. Circulation, vol.100, issue.23, pp.2312-2320, 1999. ,
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Eur Heart J, vol.374, issue.9704, pp.481-490, 1998. ,
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators, Circulation, vol.94, issue.11, pp.2807-2823, 1996. ,
Medication dosing for heart failure with reduced ejection fraction -opportunities and challenges, Eur J Heart Fail, vol.21, issue.3, pp.286-296, 2019. ,
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial, Eur J Heart Fail, vol.20, issue.2, pp.359-369, 2018. ,
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease, JACC Heart Fail, vol.7, issue.1, pp.25-32, 2019. ,
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized, Clinical Trials. Circulation, vol.138, issue.6, pp.570-577, 2018. ,
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebocontrolled study in patients with chronic heart failure (the PEARL-HF) trial, Eur Heart J, vol.32, issue.7, pp.820-828, 2011. ,
Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments, Eur Heart J Suppl, vol.21, pp.55-60, 2019. ,
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease, Eur Heart J, 2016. ,
World Heart Federation Roadmap for Heart Failure, Glob Heart, vol.14, issue.3, pp.197-214, 2019. ,
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach, Eur J Heart Fail, 2017. ,